New prostate cancer treatment improves outcome:
This article was originally published in Clinica
Combining radiotherapy with hormonal treatment could combat advanced forms of prostate cancer, according to a five-year European study of over 400 patients. Patients who received radiotherapy and 36 monthly injections of goserelin acetate (Zoladex), which inhibits the production of the sex hormone testosterone, had a survival rate of 78% compared with 62% for those treated with radiation alone, reported a team from the European Organisation for Research and Treatment of Cancer. Their findings were presented at the European Conference on Clinical Oncology in Vienna earlier this month.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.